Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant in Atherogenic Dyslipidemia in Abdominally Obese Patients
NCT00239967Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of rimonabant in atherogenic dyslipidemia (AD), abdominal obesity, sponsored by Sanofi. Started May 2005; status: completed.
02
Drugs
rimonabant
03
Conditions
atherogenic dyslipidemia (AD)abdominal obesity
Beyond the preview
Go deeper on NCT00239967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239967.